The estimated Net Worth of Foundation Harsaul is at least 25 百万$ dollars as of 13 January 2020. Foundation Harsaul owns over 1,250,000 units of Osmotica Pharmaceuticals Plc stock worth over 24,958,680$ and over the last 5 years Foundation sold OSMT stock worth over 0$.
Sign up
Foundation Harsaul OSMT stock SEC Form 4 insiders trading
Foundation has made over 1 trades of the Osmotica Pharmaceuticals Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently Foundation bought 1,250,000 units of OSMT stock worth 6,250,000$ on 13 January 2020.
The largest trade Foundation's ever made was buying 1,250,000 units of Osmotica Pharmaceuticals Plc stock on 13 January 2020 worth over 6,250,000$. On average, Foundation trades about 1,250,000 units every 0 days since 2020. As of 13 January 2020 Foundation still owns at least 22,485,297 units of Osmotica Pharmaceuticals Plc stock.
You can see the complete history of Foundation Harsaul stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Foundation Harsaul's mailing address?
Foundation's mailing address filed with the SEC is EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA, R1, 0.
Insiders trading at Osmotica Pharmaceuticals Plc
Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over 0$ worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth 31,350,366$ . The most active insiders traders include David F Burgstahler、Sriram Venkataraman、Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of 1,173,603$. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth 100,366$.
What does Osmotica Pharmaceuticals Plc do?
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
What does Osmotica Pharmaceuticals Plc's logo look like?
Complete history of Foundation Harsaul stock trades at Osmotica Pharmaceuticals Plc
Osmotica Pharmaceuticals Plc executives and stock owners
Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include:
-
Brian Markison,
Chairman of the Board, Chief Executive Officer -
Christopher Klein,
General Counsel, Secretary -
Tina deVries,
Executive Vice President - Research & Development -
James Schaub,
Chief Operating Officer, Executive Vice President -
Brian A. Markison,
Chairman, Pres & CEO -
Christopher A. Klein,
Gen. Counsel & Sec. -
James D. Schaub,
Exec. VP & COO -
Dr. Tina Marie deVries,
Exec. VP of R&D -
Andrew Einhorn,
Chief Financial Officer -
Fred Weiss,
Independent Director -
Gregory Cowan,
Independent Director -
David Burgstahler,
Director -
Sriram Venkataraman,
Director -
Juan Vergez,
Director -
Michael DeBiasi,
Independent Director -
Lisa Wilson,
IR Contact Officer -
Joachim Benes,
Director -
Andrew J. Einhorn CPA,
Chief Financial Officer -
Jarret Miller,
Exec. VP of HR -
Sergio Alegre,
VP of Global Compliance -
Capital Partners Iii Gp, L....,
-
Ltd Orbit Co Invest A 1 Llc...,
-
Foundation Harsaul,
10% owner -
Capital Partners Iii Gp, L....,